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Abstract 
The purpose of this study was to elucidate the difference in inotrope use between patients who underwent left 
ventricular assist device (LVAD) implantation with preoperative extracorporeal membrane oxygenation (ECMO) and 
those who underwent LVAD implantation without preoperative ECMO. One hundred and eight patients who under-
went LVAD implantation were enrolled in this study. Prior to LVAD implantation, 27 patients received ECMO support 
(ECMO group) and the other 81 patients did not (non-ECMO group). Cardiac index (CI), mean arterial pressure (MAP), 
mixed venous oxygen saturation (SvO2), and the vasoactive inotropic score (VIS) were recorded at weaning from 
cardiopulmonary bypass (CPB), 30 min after weaning from CPB (min after CPB), 60 min after CPB, and at the end of 
surgery. MAP and VIS were also recorded before induction of anesthesia (baseline). The modified VIS was defined as: 
(dopamine µg/kg/min × 1 + dobutamine µg/kg/min × 1 + epinephrine µg/kg/min × 100 + noradrenaline µg/
kg/min × 100 + milrinone µg/kg/min × 10 + olprinone µg/kg/min × 25). There were no significant differences 
between the ECMO group and the non-ECMO group in terms of hemodynamic parameters such as MAP, CI, and SvO2. 
However, the ECMO group had higher VIS and noradrenaline doses than that of non-ECMO group (p = 0.030 and 
p = 0.044, respectively). VIS was significantly higher in ECMO group at 30 min after CPB (p = 0.03), 60 min after CPB 
(p = 0.003), and at the end of the surgery (p < 0.001). The doses of noradrenaline were significantly higher in ECMO 
group at 60 min after CPB (p = 0.013), and at the end of surgery (p = 0.002). Patients who received ECMO support 
prior to LVAD implantation required significantly more noradrenaline to maintain normal levels of hemodynamic 
parameters compared with patients without ECMO.
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Background
Mechanical circulatory support with left ventricular 
assist devices (LVADs) is becoming increasingly impor-
tant as a therapeutic intervention for patients with 
advanced heart failure recalcitrant to medical therapy. It 
is important to set up patients eligible for transplantation 
with appropriate hemodynamic support without delay; 
otherwise death or serious morbidity may occur.
Several risk factors have been identified in regard to 
mortality after LVAD implantation (Holman et al. 2009; 
Rao et al. 2003). One of the most significant risk factors 
is preoperative cardiogenic shock. Extracorporeal mem-
brane oxygenation (ECMO) is often used to improve and 
stabilize the preoperative condition of LVAD patients. 
However, ECMO support prior to LVAD implanta-
tion has recently been reported to significantly worsen 
survival rates (Toda et  al. 2012). ECMO has also been 
associated with systemic inflammatory response (SIRS) 
(Chen et  al. 2013; Mc et  al. 2010). Hence, we hypoth-
esized that patients who receive ECMO support prior to 
LVAD implantation need higher doses of inotropes than 
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those without ECMO. The aim of this study was to eluci-
date the difference in inotrope use between patients who 
receive ECMO support prior to LVAD implantation and 
those who do not using the vasoactive inotropic score 
(VIS).
Methods
Approval for this study was obtained from the ethics 
committee at our institution, which waived the require-
ment for written informed consent from each patient 
because the retrospective registry involves no additional 
risk to the subjects. We retrospectively investigated 108 
patients with advanced heart failure who underwent 
LVAD implantation as a bridge to heart transplanta-
tion at the National Cerebral and Cardiovascular Center 
between May 1999 and September 2011. We excluded 
two patients who underwent right ventricular assist 
device implantation. Four patients whose ECMO could 
not be removed during weaning from cardiopulmo-
nary bypass (CPB) were excluded as well because the 
cardiac index (CI) and mixed venous oxygen saturation 
(SvO2) would be inaccurate in these patients. Anesthesia 
was induced with midazolam and fentanyl, and rocuro-
nium was given to facilitate orotracheal intubation with 
a cuffed tube. Anesthesia was maintained in all patients 
with propofol and fentanyl or remifentanil. All patients 
were catheterized with Swan-Ganz catheters capable of 
automatically and continuous measurement of cardiac 
output and SvO2. Inotropes, vasopressors, and vasodila-
tors are administered at the discretion of the individual 
attending anesthesiologist, depending on the hemody-
namics. The target MAP was around 60–70  mm Hg, 
and the target CI was 2.0–2.5. There were 27 patients 
who received ECMO support prior to LVAD implanta-
tion. ECMO consisted of a membrane oxygenator and a 
centrifugal pump (Capiox, Terumo, Tokyo, Japan). We 
defined these 27 patients as the ECMO group, and the 
other 81 patients as the non-ECMO group.
The patients’ clinical data were collected from clinical 
records including demographics, preoperative laboratory 
data, and intraoperative variables. CI, mean arterial pres-
sure (MAP), systemic vascular resistance index (SVRI), 
SvO2, and VIS were recorded at weaning from CPB, 
30  min after weaning from CPB (min after CPB), 60 
min after CPB, and at the end of the surgery. MAP and 
VIS were also recorded before induction of anesthesia 
(baseline).
We used a modification of the VIS described by Gaies 
et  al. (2010). We expanded this formula to include the 
inotrope olprinone, which is a phosphodiesterase 3 inhib-
itor widely used in Japan; we chose 25 as its coefficient 
because the ratio of maintenance infusion of milrinone 
(0.25  µg/kg/min) was compared with that of olprinone 
(0.1 µg/kg/min) in a previous report (Orime et al. 1999). 
Additionally, Milrila®K (Astellas, Tokyo, Japan) speci-
fies a maintenance dose range of 0.25–0.75  µg/kg/min, 
whereas Coretec® (Eisai, Japan) lists the range as 0.1–
0.3 µg/kg/min; therefore, we concluded that a coefficient 
for olprinone 2.5 times that of milrinone was appropriate.




Types of LVAD and surgical technique
All surgical procedures were performed through a 
median sternotomy during CPB. The outflow cannula 
was anastomosed to the ascending aorta and the inflow 
cannula to the left ventricular apex, without arresting the 
heart, to minimize ischemic insult to the right ventricle. 
The LVAD was then placed between the inflow and out-
flow cannulae (Toda et al. 2012). The LVADs comprised 
91 paracorporeal devices (Toyobo-VAS: Nipro), and 
17 implantable devices (two DuraHeart [Terumo]; two 
HeartMate VE [Thoratec]; four Novacor [World Heart]; 
seven Evaheart [Sun Medical]; one Jarvik 2000 [Jarvik 
Heart]; and one HeartMate II [Thoratec]).
Statistical analysis
To determine the required sample size, we estimated the 
expected difference in the mean VISs as eight, and the 
expected standard deviation as 12. A power of 0.8 and an 
α of 0.05 were used to determine that 24 patients in the 
ECMO group would be appropriate. Hemodynamic data, 
VIS, and each inotrope dose were subjected to repeated-
measures ANOVA. If the difference between the groups 
was significant, an independent t test was used to deter-
mine the difference at each time point.
Statistical significance was set at a level of 0.05. All 
statistical analyses were performed with EZR (Saitama 
Medical Center, Jichi Medical University, Saitama, Japan), 
which is a graphical user interface for R (R Foundation for 
Statistical Computing, Vienna, Austria). More precisely, 
it is a modified version of an R commander designed to 
add statistical functions frequently used in biostatistics 
(Kanda 2013).
Results
Table 1 shows the demographic data of all patients. Pre-
operative variables and intraoperative characteristics in 
the ECMO group and the non-ECMO group are shown 
in Table 2. There were no significant differences between 
groups in sex, age, body surface area, body mass index, 
aspartate aminotransferase, alanine aminotransferase, 
serum B-type natriuretic peptide level, anesthesia time, 
operation time, CPB time, and blood loss. However, a 
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larger number of patients in the ECMO group required 
preoperative intra-aortic balloon pump support, 
mechanical ventilation, and intraoperative nitric oxide 
use. Serum total bilirubin, serum creatinine, and serum 
blood urea nitrogen (BUN) were significantly higher in 
the ECMO group. White blood cell count and C-reactive 
protein levels before LVAD implantation were signifi-
cantly higher in the ECMO group. Hemoglobin, platelet 
count, serum total protein, and albumin levels were sig-
nificantly lower in the ECMO group.
There was no significant difference between the group in 
terms of baseline MAP (70.6 ± 15.0 mm Hg in the ECMO 
group, 67.8  ±  14.0  mm Hg in the non-ECMO group, 
p = 0.395). The hemodynamic changes in both groups are 
shown in Table  3. There were no significant differences 
between the ECMO group and the non-ECMO group 
in terms of hemodynamic parameters such as MAP, CI, 
SVRI, and SvO2. However, changes in the VIS were signifi-
cantly different between groups (Table 4, p = 0.030). Each 
dose of inotrope was compared by repeated-measures 
ANOVA, which revealed that only the noradrenaline dose 
Table 1 Preoperative patient characteristics
Data are presented as mean ± SD, or number (%)
BSA body surface area, BMI body mass index, BNP brain natriuretic peptides, 
IABP intra-aortic balloon pump, ECMO extracorporeal membrane oxygenation, 
LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic 
diameter, LVEF left ventricular ejection fraction
Characteristic Number or mean ± SD
Sex (M/F) 76/32
Age (year) 34.6 ± 12.8
BSA (m2) 1.55 ± 0.20
BMI (kg/m2) 19.4 ± 3.7
Serum total bilirubin (mg/dl) 2.3 ± 2.3
Serum creatinine (mg/dl) 1.4 ± 1.1
Serum BNP (pg/ml) 1436 ± 994
Preoperative IABP support 64 (59.3)
Preoperative ECMO 27 (25.0)
LVEDD (mm) 73 ± 11
LVESD (mm) 66 ± 11
LVEF (%) 17 ± 9
Table 2 Preoperative variables and intraoperative characteristics in both groups
Data are presented as mean ± SD, or number (%)
ECMO extracorporeal membrane oxygenation, BSA body surface area, BMI body mass index, IABP intra-aortic balloon pump, AST aspartate aminotransferase, ALT 
alanine aminotransferase, BUN blood urea nitrogen, BNP brain natriuretic peptides, CPB cardiopulmonary bypass, NO nitric oxide
ECMO group (n = 27) Non-ECMO group (n = 81) p value
Sex (male) 19 (70.4) 57 (70.4) 1.000
Age (year) 33.4 ± 12.4 35.0 ± 13.0 0.573
BSA (m2) 1.53 ± 0.18 1.56 ± 0.21 0.593
BMI (kg/m2) 18.6 ± 2.7 19.6 ± 3.9 0.216
Preoperative IABP support 24 (88.9) 40 (49.4) <0.001
Preoperative mechanical ventilation 22 (81.5) 7 (8.6) <0.001
White blood cell count(/ml) 8580 ± 2961 10,789 ± 4706 0.006
Hemoglobin (g/dl) 10.2 ± 1.8 11.3 ± 1.9 0.009
Platelet count (x104/ml) 13.0 ± 7.9 24.4 ± 24.4 0.022
C-reactive protein (mg/dl) 6.1 ± 4.6 3.1 ± 3.3 <0.001
Serum total bilirubin (mg/dl) 3.7 ± 3.8 1.9 ± 1.3 <0.001
Serum total protein (g/dl) 6.0 ± 0.7 6.4 ± 0.7 0.015
Serum albumin (g/dl) 3.3 ± 0.7 3.6 ± 0.5 0.010
AST (IU/L) 243 ± 507 124 ± 315 0.157
ALT (IU/L) 182 ± 350 178 ± 392 0.959
Serum creatinine (mg/dl) 1.9 ± 1.8 1.2 ± 0.7 0.006
Serum BUN (mg/dl) 40 ± 26 29 ± 19 0.024
Serum BNP (pg/ml) 1380 ± 985 1453 ± 1003 0.772
Anesthesia time (min) 522 ± 140 511 ± 169 0.767
Operation time (min) 423 ± 132 398 ± 151 0.444
CPB time (min) 161 ± 60 156 ± 59 0.689
NO use in operation 16 (59.3) 25 (30.9) 0.008
Blood loss (ml) 3054 ± 3010 2177 ± 2188 0.114
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was significantly different between the groups (p = 0.044). 
Figure  1 shows the VIS for both groups; an independent 
t-test revealed that the VIS was significantly higher in 
ECMO group at 30 min after CPB (p = 0.03), 60 min after 
CPB (p = 0.003), and at the end of the surgery (p < 0.001). 
Figure  2 shows the noradrenaline dose for both groups 
during LVAD implantation surgery; an independent t-test 
revealed that the doses of noradrenaline were significantly 
higher in ECMO group at 60 min after CPB (p = 0.013), 
and at the end of surgery (p = 0.002).
Discussion
Patients who received ECMO support prior to LVAD 
implantation required significantly more vasopressor 
support compared with those who did not receive pre-
operative ECMO support. This was most likely caused by 
the patients’ low systemic vascular resistance concomi-
tant with the occurrence of SIRS during ECMO (Mc et al. 
2010).
Although the pathophysiology is not completely under-
stood, previous studies have revealed that cardiac sur-
gery using CPB induces SIRS (Cremer et al. 1996; Laffey 
et  al. 2002; Delannoy et  al. 2009). Inflammatory media-
tors are activated and released from blood cells as a 
result of exposure to the artificial surfaces of the extra-
corporeal circuit, surgical trauma, hypothermia, and 
tissue ischemia–reperfusion (Belhaj 2012; Kozik and 
Tweddell 2006). Cytokines play an important part in the 
Table 3 Hemodynamic changes in both groups
Data are presented as mean ± SD
CPB cardiopulmonary bypass, MAP mean arterial pressure, CI cardiac index, SVRI systemic vascular resistance index, SvO2 mixed venous oxygen saturation, ECMO 
extracorporeal membrane oxygenation
a compared between the two groups
Group End of CPB 30 min after CPB 60 min after CPB End of surgery p valuea
MAP (mm Hg) Non-ECMO group 66.4 ± 11.5 70.7 ± 12.2 72.5 ± 9.8 74.1 ± 16.2 0.295
ECMO group 68.8 ± 10.1 68.3 ± 13.2 68.4 ± 13.4 70.1 ± 11.5
CI (L/min/m2) Non-ECMO group 2.5 ± 0.9 2.4 ± 1.1 2.5 ± 0.8 2.6 ± 0.6 0.989
ECMO group 2.2 ± 1.3 2.4 ± 0.6 2.4 ± 0.5 2.6 ± 0.6
SVRI (dynes s/cm5/m2) Non-ECMO group 2120 ± 945 2139 ± 822 2214 ± 803 2082 ± 777 0.808
ECMO group 2489 ± 844 2197 ± 670 2184 ± 898 1962 ± 518
SvO2 (%) Non-ECMO group 78.2 ± 8.7 75.3 ± 13.3 74.8 ± 7.5 73.8 ± 8.3 0.120
ECMO group 73.6 ± 13.7 70.0 ± 12.2 69.9 ± 9.2 68.2 ± 8.4
Table 4 Change in vasoactive inotrope score and catecholamine dose in both groups
Data are presented as mean (1st quartile–3rd quartile)
VIS vasoactive inotrope score, CPB cardiopulmonary bypass, DOA dopamine, DOB dobutamine, NAD noradrenaline, AD adrenaline
a compared between the non-ECMO group and the ECMO group
Group Baseline End of CPB 30 min after CPB 60 min after CPB End of surgery p valuea
VIS Non-ECMO group 13.2 (5.7–16.0) 22.1 (9.4–23.0) 16.8 (8.7–20.0) 16.3 (9.5–17.5) 14.7 (8.8–16.6) 0.030
ECMO group 13.4 (8.1–16.0) 24.9 (12.7–26.4) 24.7 (12.1–25.3) 26.1 (12.3–33.3) 25.5 (12.7–31.7)
DOA (µg/kg/min) Non-ECMO group 3.3 (0–5.0) 3.8 (3.0–5.0) 3.8 (3.0–5.0) 3.8 (3.0–5.0) 3.8 (3.0–5.0) 0.250
ECMO group 3.4 (1.8–4.9) 4.1 (3.0–5.0) 4.3 (3.3–5.0) 4.2 (3.0–5.0) 4.0 (3.0–5.0)
DOB (µg/kg/min) Non-ECMO group 5.3 (3.5–7.0) 2.0 (0–3.5) 2.2 (0–3.9) 2.2 (0–4.0) 2.6 (0–4.4) 0.908
ECMO group 5.0 (3.8–6.5) 2.2 (0–4.5) 2.3 (0–4.8) 2.2 (0–4.3) 2.5 (0–4.3)
NAD (µg/kg/min) Non-ECMO group 0.02 (0–0) 0.10 (0–0.12) 0.08 (0–0.1) 0.07 (0–0.08) 0.05 (0–0.05) 0.044
ECMO group 0.03 (0–0) 0.14 (0–0.13) 0.14 (0–0.15) 0.15 (0–0.17) 0.13 (0–0.18)
AD (µg/kg/min) Non-ECMO group 0.001 (0–0) 0 (0–0) 0.001 (0–0) 0.001 (0–0) 0.004 (0–0) 0.162
ECMO group 0.006 (0–0) 0.004 (0–0) 0 (0–0) 0 (0–0) 0.013 (0–0)
Milrinone (µg/kg/min) Non-ECMO group 0.2 (0–0.4) 0.2 (0–0.4) 0.2 (0–0.4) 0.2 (0–0.4) 0.2 (0–0.4) 0.580
ECMO group 0.1 (0–0.2) 0.2 (0–0.5) 0.2 (0–0.5) 0.2 (0–0.5) 0.2 (0–0.5)
Olprinone (µg/kg/min) Non-ECMO group 0.004 (0–0) 0.1 (0–0) 0.05 (0–0) 0.05 (0–0) 0.05 (0–0) 0.847
ECMO group 0.003 (0–0) 0.1 (0–0) 0.10 (0–0.3) 0.10 (0–0.3) 0.08 (0–0.2)
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inflammatory reaction caused by surgical trauma; they 
mediate the local inflammatory response, resulting in 
systemic changes (Gozdzik et al. 2014).
Although there are some pathophysiological differ-
ences between CPB and ECMO, almost all patients 
treated with ECMO are associated with SIRS, which is 
characterized by a “cytokine storm”, leukocyte activation, 
and multisystem organ dysfunction (Mc et al. 2010; Chen 
et al. 2013). An animal model study revealed that animals 
given ECMO support develop tachycardia and hypoten-
sion within 1–2 h of ECMO initiation (Mc et al. 2010).
In our study, patients who received preoperative 
ECMO support needed more vasopressor to maintain 
normal MAP levels. This may indicate that hypotension 
is enhanced by the synergetic effect of the cytokine storm 
caused by ECMO and CPB. The baseline VIS (before 
induction of anesthesia) was not different between the 
groups; therefore, the synergetic effect of both ECMO 
and CPB may have decreased systemic vascular resist-
ance, which resulted in more vasopressor being required 
to maintain blood pressure. In the current study, serum 
total bilirubin, serum creatinine, and serum BUN were 
significantly higher in the ECMO group; this may 
reflect that patients who required ECMO support did 
not recover from preoperative end-organ dysfunction 
because of cardiogenic shock. Preoperative white blood 
cell count and serum C-reactive protein level were also 
significantly higher in the ECMO group, suggesting 
that preoperative SIRS induced by ECMO may have an 
impact on hemodynamics. Bertrand et  al. investigated 
the association between biological markers and CPB-
induced SIRS. They found that baseline C-reactive pro-
tein is significantly higher in patients with SIRS than in 
patients without SIRS (6.7 vs 1.8 mg/l, p = 0.016) (Delan-
noy et al. 2009). This agrees with our result in which the 
baseline C-reactive protein was significantly higher in the 
ECMO group, who needed more vasopressor because of 
SIRS induced by ECMO and CPB.
In our study, inotropes, vasopressors, and vasodila-
tors were administered at the discretion of the individual 
attending anesthesiologist, depending on the hemody-
namics and real-time transesophageal echocardiography. 
However, there was no difference between the groups 
in terms of the hemodynamic parameters such as MAP, 
CVP, SVRI, and SvO2. It follows that the target hemo-
dynamics were the same in both groups. Each attend-
ing anesthesiologist used noradrenaline as a vasopressor 
to maintain systemic vascular resistance within normal 
range. However, we were unable to determine whether 
this method of vasopressor use improved the outcome of 
the patients who had received preoperative ECMO sup-
port. Few studies to date have demonstrated a significant 
survival benefit of one vasopressor over another. Further 
study is necessary to demonstrate that the use of a vaso-
pressor can improve the outcome of patients after LVAD 
implantation.
There were some limitations to this study. First, the 
number of patients was relatively small. We conducted 
Fig. 1 Change in vasoactive inotrope score during left ventricular 
assist device implantation in patients who received extracorporeal 
membrane oxygenation (ECMO) compared with those who did not. 
All data are expressed as mean (filled symbols) ± SD (bars). The filled 
circles and solid line represents the non-ECMO group, and the filled 
triangles and dotted line represents the ECMO group. ECMO extra-
corporeal membrane oxygenation, CPB cardiopulmonary bypass. 
*p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2 Change in noradrenaline dose required during left ventricular 
assist device implantation in patients who received extracorporeal 
membrane oxygenation (ECMO) compared with those who did not. 
All data are expressed as mean (filled symbols) ± SD (bars). The filled 
circles and solid line represents the non-ECMO group, and the filled 
triangles and dotted line represents the ECMO group. ECMO extracor-
poreal membrane oxygenation, NAD noradrenaline, CPB cardiopul-
monary bypass. *p < 0.05, **p < 0.01
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a power analysis to determine the minimum number 
required for each group. Because no previous studies 
comparable to ours have been conducted, we empirically 
designated the difference in the VIS means as eight. The 
variance of VIS was computed based on the VIS variance 
of the first 20 patients. Although we conducted a power 
analysis, it is possible that the ideal sample size is larger 
than presented here because of the empirical process. 
Second, this study was retrospective and the accuracy 
of chart documentation cannot be guaranteed. Besides, 
we cannot eliminate the other multiple factors affect-
ing vasodilatory responses other than ECMO, including 
multi-organ failure, use of IABP, mechanical ventilation, 
possibly intraoperative blood loss or dosage of phospho-
diesterase inhibitor. Third, the coefficient of olprinone in 
modified VIS may be inaccurate because it was defined 
based on the study with small number of patients. Finally, 
this was a single-center study, and thus our findings may 
not be generalizable to other patient populations.
Conclusions
In conclusion, patients supported by ECMO prior 
to LVAD implantation required significantly more 
noradrenalineto maintain normal hemodynamic param-
eters compared with patients without ECMO.
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